Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1080/14712598.2016.1195364 http://scihub22266oqcxt.onion/10.1080/14712598.2016.1195364 C5045799!5045799 !27248342     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=27248342 &cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Expert+Opin+Biol+Ther 2016 ; 16 (9 ): 1105-12 Nephropedia Template TP {{tp|p=27248342 |t=2016. Designing multivalent proteins based on natural killer cell receptors and their ligands as immunotherapy for cancer |pdf=|usr=}}{{27248342 }} gab.com Text Designing multivalent proteins based on natural killer cell receptors and their ligands as immunotherapy for cancer JO: Expert Opin Biol Ther http://www.kidney.de/pget.php?&tw=1&pmid=27248342 #FOAvip INTRODUCTION: Natural killer (NK) cells are an important component of the innate immune system that play a key role in host immunity against cancer. NK cell recognition and activation is based on cell surface receptors recognizing specific ligands that are expressed on many types of tumor cells. Some of these receptors are capable of activating NK cell function while other receptors inhibit NK cell function. Therapeutic approaches to treat cancer have been developed based on preventing NK cell inhibition or using NK cell receptors and their ligands to activate NK cells or T cells to destroy tumor cells. AREAS COVERED: This article describes the various strategies for targeting NK cell receptors and NK cell receptor ligands using multivalent proteins to activate immunity against cancer. EXPERT OPINION: NK cell receptors work in synergy to activate NK cell effector responses. Effective anti-cancer strategies will need to not only kill tumor cells but must also lead to the destruction of the tumor microenvironment. Immunotherapy based on NK cells and their receptors has the capacity to accomplish this through triggering lymphocyte cytotoxicity and cytokine production. Twit Text FOAVip Designing multivalent proteins based on natural killer cell receptors and their ligands as immunotherapy for cancer ????Expert Opin Biol Ther http://www.kidney.de/pget.php?&tw=1&pmid=27248342 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=27248342 #FOAvip English Wikipedia <ref>{{Cite pmid|27248342 }}</ref> Designing multivalent proteins based on natural killer cell receptors and their ligands as immunotherapy for cancer #MMPMID27248342 Smits NC ; Coupet TA ; Godbersen C ; Sentman CL Expert Opin Biol Ther 2016[Sep]; 16 (9 ): 1105-12 PMID27248342 show ga INTRODUCTION: Natural killer (NK) cells are an important component of the innate immune system that play a key role in host immunity against cancer. NK cell recognition and activation is based on cell surface receptors recognizing specific ligands that are expressed on many types of tumor cells. Some of these receptors are capable of activating NK cell function while other receptors inhibit NK cell function. Therapeutic approaches to treat cancer have been developed based on preventing NK cell inhibition or using NK cell receptors and their ligands to activate NK cells or T cells to destroy tumor cells. AREAS COVERED: This article describes the various strategies for targeting NK cell receptors and NK cell receptor ligands using multivalent proteins to activate immunity against cancer. EXPERT OPINION: NK cell receptors work in synergy to activate NK cell effector responses. Effective anti-cancer strategies will need to not only kill tumor cells but must also lead to the destruction of the tumor microenvironment. Immunotherapy based on NK cells and their receptors has the capacity to accomplish this through triggering lymphocyte cytotoxicity and cytokine production. |*Drug Design [MESH] |Animals [MESH] |Antibodies, Monoclonal/pharmacology/therapeutic use [MESH] |Clinical Trials as Topic/methods [MESH] |Cytotoxicity, Immunologic/drug effects/immunology [MESH] |Humans [MESH] |Immunotherapy/*methods [MESH] |Killer Cells, Natural/drug effects/*immunology [MESH] |Ligands [MESH] |Neoplasms/*immunology/*therapy [MESH] |Receptors, Immunologic/antagonists & inhibitors/immunology [MESH] |Receptors, Natural Killer Cell/antagonists & inhibitors/*immunology [MESH]Designing multivalent proteins based on natural killer cell receptors (epmc).pdf DeepDyve Pubget Overpricing